Biologics continue to increase in number, both in approved products and in products in development. Many of the biggest selling products are biologics, and in particular biologics arising from a monoclonal antibody. 21 FDA approved therapies – including eight blockbuster drugs, are monoclonal antibody based. In 2007, the US market was worth $21.9bn. (Bioportfolio, Therapeutic Monoclonal Antibody Report 2008-2023). For example, some of the biggest are Remicade® (Johnson & Johnson, Schering-Plough, Tanabe) and Enbrel® (Amgen, Wyeth) for Rheumatoid arthritis, Rituxan®, (MabThera Roche, Genentech, Biogen Idec, Chugai Pharmaceutical) for Non-Hodgkin’s lymphoma and Herceptin® (Roche, Genentech, Chugai Pharmaceutical) for Breast cancer rank 12, and Avastin® (Roche, Genentech) for Colorectal cancer, having combined worldwide sales of over $20bn in 2008. (Krishan Maggon, https://knol.google.com/k/krishan-maggon/world-top-ten-biotechnologybiologics/3fy5eowy8suq3/16#).
Click the link below to read the full alert.